Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio
Key Highlights
- ➤Microbot Medical (MBOT) receives patent approvals across the U.S., Japan, China and Canada
- ➤Microbot now holds 44 issued patents and 49 pending applications globally
- ➤LIBERTY commercialization advances in U.S. markets as Microbot pursues a CE Mark
- ➤Patent portfolio expansion supports planned EU and other international market entry
Expert Statements
Dr. Sarit Garten, Director of Intellectual Property at Microbot Medical
“Our commercial growth since the launch of LIBERTY goes hand in hand with our strategy to enhance and strengthen our intellectual property portfolio while simultaneously building the global infrastructure needed to support broader market access for the LIBERTY System”
Dr. Sarit Garten, Director of Intellectual Property at Microbot Medical
“Our R&D and Business Development teams’ ongoing collaboration is resulting in a robust and diverse intellectual property portfolio, which we expect to expand significantly over the coming months.”
Dr. Sarit Garten, Director of Intellectual Property at Microbot Medical
“These developments align with our strategy for market entry into the EU and other jurisdictions.”
The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets.
HINGHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has received several new patent approvals across the U.S., Japan, China and Canada, further strengthening its global intellectual property portfolio as the Company continues to expand commercial adoption of the LIBERTY® System in the U.S. and position it for growth in key international markets as it pursues a CE Mark. As a result of these latest developments, the Company now holds 44 issued patents and 49 pending patent applications across North America, Europe, Israel, and Asia.
Get started
Create a free account to read the full story.